⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21244660 | 1.00 | — | — | |
| SCHEMBL21274906 | 0.95 | — | — | |
| SCHEMBL21274995 | 0.94 | — | — | |
| SCHEMBL21244830 | 0.94 | — | — | |
| SCHEMBL28506056 | 0.90 | BRD4 (0.36) | — | |
| SCHEMBL22982903 | 0.90 | BRD4 (0.36) | — | |
| SCHEMBL21244828 | 0.89 | MEN1 (0.30) | — | |
| SCHEMBL21275283 | 0.86 | BRD4 (0.32) | — | |
| SCHEMBL21244877 | 0.86 | BRD4 (0.32) | — | |
| SCHEMBL22975191 | 0.85 | ARG1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013741-B1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMA (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11873300-B2 | Crystalline forms of CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-16 | — | — | US | disclosed |
| US-11866450-B2 | Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-12-14 | — | — | US | disclosed |
| US-20230303589-A1 | CRYSTALLINE FORMS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-09-28 | — | — | US | disclosed |
| EP-4218754-A2 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4198037-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4196221-A1 | CRYSTALLINE FORMS OF CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2023-06-21 | — | — | EP | disclosed |
| US-11591350-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3880197-B1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021030556-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030554-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030552-A1 | CRYSTALLINE FORMS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030555-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047350-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-18 | — | — | US | disclosed |
| US-20210047323-A1 | CRYSTALLINE FORMS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2021-02-18 | — | — | US | disclosed |
| EP-3752510-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | Vertex Pharmaceuticals Incorporated (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020102346-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2019161078-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190248809-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-15 | — | — | US | disclosed |